期刊
HIV CLINICAL TRIALS
卷 11, 期 3, 页码 127-132出版社
TAYLOR & FRANCIS LTD
DOI: 10.1310/hct1103-125
关键词
efavirenz; HIV-1; maraviroc; treatment naive; virologic response
资金
- Pfizer Global Research and Development
- Pfizer, Inc.
- ViiV Healthcare
- Merck Sharp Dohme
- Tibotec
- Stendhal
- Abbott
- Gilead
- BMS
- GlaxoSmithKline
- Ardea Biosciences Avexa
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- Pain Therapeutics
- Progenics
- Tobira Therapeutics
- Virxsys
Background: The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naive patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay. Methods: Week 96 efficacy (post hoc, n = 614) and safety (n = 721) were assessed. Results: Proportions of subjects <50 copies/mL (58.8% maraviroc, 62.7% efavirenz) and time to loss of virologic response (TLOVR) responders (<50 copies/mL: 60.5% vs 60.7%) were similar. Maraviroc recipients had greater CD4 increases (+212 vs+ 171 cells/mm(3)) and fewer adverse event discontinuations (6.1% vs 15.5%), malignancies, and category C events. Conclusion: Week 96 data confirm week 48 observations in MERIT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据